GUANGZHOU, China, Oct. 8, 2024
/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:
BDMD) ("Baird Medical" or the "Company"), a leading microwave
ablation ("MWA") medical device developer and provider
in China which has recently expanded into the U.S. market
following its receipt of US FDA 510(k) clearances, today announced
that the Company will participate in the following investor
conference. Baird Medical's management plans to host one-on-one and
small group meetings with institutional investors at the
conference.
Roth's 3rd Annual Healthcare Opportunities
Conference
Wednesday, October 9,
2024
Metropolitan Club, 1 E 60th Street, New York, NY, 10022
Baird Medical's participation in the event comes as the Company
expands its footprint in the U.S. market following recent FDA
clearance for its minimally invasive microwave ablation technology,
which offers a promising alternative to thyroidectomy for patients
with benign thyroid tumors. Currently, 150,000 thyroidectomies are
performed in the U.S. annually.
About Baird Medical
Established in 2012 and headquartered in Guangzhou,
China, Baird Medical is a leading
microwave ablation ("MWA") medical device manufacturer and provider
in China and a recent entrant to the United
States market. Baird Medical's proprietary medical devices are
used for the treatment of benign and malignant tumors including
thyroid nodules, liver cancer, lung nodules and breast lumps. Baird
Medical is the first company to obtain a Class III medical devices
registration certificate for MWA medical devices specifically
indicated for thyroid nodules in China. For more information,
please visit http://www.bairdmed.com/.
Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: BairdMedical.IR@icrinc.com
Public Relations
Brad Burgess, Senior Vice
President
ICR, LLC
Phone: +1 (646) 588-0383
Email: BairdMedical.PR@icrinc.com
View original
content:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-roths-3rd-annual-healthcare-opportunities-conference-302270307.html
SOURCE Baird Medical Investment Holdings Ltd.